ArticleFrontiers in public health2025
Global trends, decomposition analysis, inequality assessment, and economic projections of tracheal, bronchus, and lung cancer.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study analyzed global trends in incidence, mortality, disability-adjusted life years (DALYs), and economic burden of tracheal, bronchus, and lung (TBL) cancer from 1990 to 2021, focusing on regional and sex differences, with projections to 2050. Methods: Using joinpoint regression to assess temporal trends. Decomposition analysis quantified the effects of population growth, aging, and changes in disease fatality. Health inequalities were evaluated using the concentration index (CI), and the economic burden was estimated through a value of statistical life (VSL). Results: Globally, TBL cancer deaths increased from 1.08 million in 1990 to 2.02 million in 2021, and DALYs rose from 28.46 million to 46.54 million, with a sharper rise among females. Population growth (94.18%) and population aging (36.07%) were the major components to the observed increase in the global TBL cancer burden. East Asia accounted for over half of the global increase, with China contributing the largest national share. The global economic burden is projected to rise from $3.86 trillion in 2021 to $7.15 trillion by 2050. China's economic loss from TBL cancer is estimated to increase from $688 billion in 2021 to $2.49 trillion by 2050, surpassing the United States and reflecting the rapid escalation of burden in Asia. Conclusion: TBL cancer remains a major global health challenge, requiring urgent, region-specific action to reduce its growing impact.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.